Home » AstraZeneca to Start Long-Term Brilinta Heart Attack Study
AstraZeneca to Start Long-Term Brilinta Heart Attack Study
AstraZeneca Plc plans to see if its new blood-thinning drug Brilinta improves the health of heart attack patients up to three years later.
Bloomberg
Bloomberg
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May